Drugs / SIG-005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05665036 | Nov 2021 → Dec 2022 | Hurler-Scheie syndrome, Scheie syndrome | Sigilon Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIG-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05665036 ↗ |
| Modality | Cell therapy | “an encapsulated allogeneic cell therapy genetically modified with a non-viral vector” NCT05665036 ↗ |
| Route | Other | “Laparoscopic administration of SIG-005 spheres” NCT05665036 ↗ |